Ryan Sowell

Ifm Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

12h-index2.8kcitations45works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(30), Immune Cell Function and Interaction(26), Cancer Immunotherapy and Biomarkers(24), T-cell and B-cell Immunology(12), CAR-T cell therapy research(5)

Publications45 total

Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology·2025· 1 cited
Abstract 3472: STX-003: cancer immunotherapy with systemic delivery of mRNA utilizing programmable genetic circuits for precise regulation of IL-12 expression and reduced toxicity
Cancer Research·2025· 1 cited
1328 STX-003: utilizing programmable genetic circuits for tumor-specific IL-12 expression and reduced toxicity with systemically delivered mRNA
Regular and Young Investigator Award Abstracts·2024Open Access
A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.
Journal of Clinical Oncology·2024· 5 cited
Abstract 2731: STX-001, a locally administered LNP-formulated self-replicating mRNA that encodes the therapeutic payload IL-12, induces deep systemic immune responses to solid tumors
Cancer Research·2023· 2 cited
Supplementary Methods from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Supplementary Figure Legends from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S1 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Supplementary Figures from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S1 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Data from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S2 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Supplementary Figures from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Data from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S3 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S3 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Table S2 from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Supplementary Figure Legends from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Supplementary Methods from Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
2023Open Access
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
International Journal of Radiation Oncology*Biology*Physics·2018· 13 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Scott Gettinger(20), Sarah B. Goldberg(20), Kurt A. Schalper(20), Roy S. Herbst(20), Anne C. Chiang(19), Ila Datar(18), Richard P. Lifton(18), Paula Kavathas(18), David L. Rimm(18), Susan M. Kaech(18), Katerina Politi(18), Jungmin Choi(17), Anna Truini(17), Anna Wurtz(17), Weilai Dong(17), Guoping Cai(17), Mary Ann Melnick(17), Joseph Schlessinger(17), Victor Y. Du(16), Miguel F. Sanmamed(16)